Signal of the Day · Regulation & Policy
FDA deregulation relocates AI-oversight cost onto hospitals, not away
As the FDA lightens front-end review, oversight cost shifts to back-end model-drift monitoring, hospital governance, and provider-side liability under the learned-intermediary doctrine; healthcare organizations that buy AI now own governing it across its life cycle.